Pharma’s Next Operating Model: Governed Intelligence, Not Automation for Its Own Sake

For pharmaceutical CXOs, digital transformation is no longer a technology program delegated to individual plants. It is an operating-model decision about how quality, data, manufacturing, and people will work together at enterprise scale. The clearest message from recent industry discussions is that the hard problem is governance, not technology. Leaders are therefore shifting attention from isolated pilots toward connected capabilities that can improve quality, resilience, speed, and decision-making without weakening regulatory accountability.

Industrial AI illustrates both the opportunity and the caution. In manufacturing, AI can support process design, advanced process control, fault detection, visual inspection, and trend analysis. Yet in a GMP environment, a promising algorithm is not enough. FDA’s current direction emphasizes human-centric design, a clearly defined context of use, data governance, risk-based performance assessment, and lifecycle management. For executives, this changes the investment question from “Where can we deploy AI?” to “Which decisions may AI influence, who remains accountable, and how will performance, drift, and change be governed?”

This is why connected manufacturing foundations matter. Automation, process control, manufacturing execution, electronic records, contextualized data, and analytics need to work as an integrated information chain. Without trustworthy data and consistent operational context, enterprise AI cannot scale responsibly. MES and manufacturing intelligence should therefore be viewed less as standalone digital projects and more as the backbone linking shop-floor events with quality review, business decisions, and multi-site learning. Cybersecurity must be designed into that backbone because greater connectivity also increases operational and data-integrity exposure.

Digital twins and process models add another layer of value. A digital twin combines a representation of the physical process with operational data, simulation, and analytics to support decisions. Mechanistic models can deepen scientific understanding; data-driven models can identify patterns; and hybrid models combine both. Their practical value lies in process design, scale-up, monitoring, and control—not in creating a fashionable virtual replica. ICH’s advanced-manufacturing work also makes the executive challenge explicit: model validation, intended use, risk classification, maintenance, and change management must be addressed across the lifecycle.

Continuous manufacturing shows how digital and physical modernization can converge. ICH Q13 establishes lifecycle expectations for continuous manufacturing, including control strategy, process dynamics, real-time monitoring, material traceability, and model maintenance. Continuous process verification can use ongoing data to strengthen process understanding and identify variability earlier. The strategic promise is not simply more automation; it is greater agility, more assured quality, and a more resilient supply network. Importantly, highly autonomous plants remain an industry aspiration—not a regulatory destination. Human oversight, qualified decision rights, and robust pharmaceutical quality systems remain essential.

The CXO agenda is therefore integration with accountability. Leaders should align quality, operations, IT, engineering, and cybersecurity around a common transformation portfolio; fund scalable data and control foundations rather than disconnected demonstrations; and build multidisciplinary capability to govern models after deployment. The organizations that progress fastest will not be those that automate every decision. They will be those that know which decisions to augment, which to retain with people, and how to demonstrate that the complete manufacturing system remains in control.